ATTR amyloidosis

HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR )...


Full positive results from the HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment...


A study led by researchers from the Amyloidosis Center at Boston University School of Medicine ( BUSM ) and Boston...